← Leaderboards
Leila Hejazi
Sygnamap, Inc.
$485,115
Attributed
$970,229
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $607.2K · FY2021–23$1M$750K$500K$250K$0
'21
'22
'23
Funding mix
By agency
NIH$970,229 · 3
By mechanism
R43$662,999 · 2
R41$307,230 · 1
Top collaborators
- Kumar Sharma2 shared
- Guanshi Zhang2 shared
Others in their field
Other Emerging Leaders on “Biological Markers”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,644,754
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$206,375,181
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,483,553
- Leonard Freedmand · Leidos Biomedical Research, Inc.$64,555,721
- Yunda Huang · Fred Hutchinson Cancer Center$54,118,126
- Susan Abushakra · Alzheon, Inc.$50,765,244
Research focus
Biological MarkersStructureTechnologyPathway InteractionsKidney DiseasesPrecision TherapeuticsImageCostSmall Business Innovation Research GrantBiotechnologyTissuesBaseDrug DevelopmentInnovationLinkComputational PlatformKidneyBiopsyPathologyBiochemicalInsightFutureHeterogeneityInterest
Grant awards (4)
Quantitative Normalization of Spatial Metabolomics for Molecular Signatures of Tissue Heterogeneity$356,499
R43 · FY2023 · GM · contact PI
Precision Mass Spec Imaging Based Structure-Function Signatures of Diabetic Glomerulopathy$6,500
R43 · FY2022 · DK · contact PI
On-chip filtration and fractionation components for high-sensitive POC device to measure Chiral Metabolites in Urine$307,230
R41 · FY2021 · GM · contact PI
Precision Mass Spec Imaging Based Structure-Function Signatures of Diabetic Glomerulopathy$300,000
R43 · FY2021 · DK · contact PI